Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 10/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | CDC25A | P30304 | 1/20 | 0.43 |
| ▸ | CDC25B | P30305 | 1/20 | 0.43 |
| ▸ | CDC25C | P30307 | 1/20 | 0.43 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.43 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | PI4KA | P42356 | 1/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.41 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL450076 | 0.90 | TGFBR1 (0.52) | TGFBR1MAPK14CYP19A1NPC1MEN1 | |
| SCHEMBL412299 | 0.87 | TGFBR1 (0.49) | TGFBR1MAPK14CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL415672 | 0.83 | TGFBR1 (0.52) | TGFBR1MAPK14CYP19A1PIK3CDPIK3CA | |
| SCHEMBL413765 | 0.83 | TGFBR1 (0.52) | TGFBR1MAPK14CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL415611 | 0.78 | TGFBR1 (0.52) | TGFBR1MAPK14CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL5956439 | 0.78 | TGFBR1 (0.64) | TGFBR1MAPK14CYP19A1NPC1MEN1 | |
| SCHEMBL5956505 | 0.77 | TGFBR1 (0.55) | TGFBR1MAPK14CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL5956501 | 0.76 | TGFBR1 (0.56) | TGFBR1MAPK14MEN1 | |
| SCHEMBL6409107 | 0.76 | AR (0.47) | TGFBR1CYP1A2NPC1PIK3CASMN1; SMN2 | |
| SCHEMBL6998890 | 0.76 | TGFBR1 (0.55) | TGFBR1MAPK14NPC1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060004051-A1 | Compounds | DODIC NERINA | 2006-01-05 | — | — | US | claimed |
| EP-1554275-A2 | COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-07-20 | — | — | EP | claimed |
| JP-2004524302-A | — | — | 2004-08-12 | — | — | JP | claimed |
| US-20040077687-A1 | Thiazolmines and their use as tgf-beta inhibitors | GLAXO GROUP LIMITED (GB) | 2004-04-22 | — | — | US | claimed |
| WO-2004013134-A2 | COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-02-12 | — | — | WO | claimed |
| EP-1355870-A1 | THIAZOLAMINES AND THEIR USE AS TGF-BETA INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-10-29 | — | — | EP | claimed |
| WO-2002062753-A1 | THIAZOLAMINES AND THEIR USE AS TGF-BETA INHIBITORS | GLAXO GROUP LIMITED (GB) | 2002-08-15 | — | — | WO | claimed |
| US-20140120621-A1 | TGF-BETA RECEPTOR INHIBITORS TO ENHANCE DIRECT REPROGRAMMING | THE GENERAL HOSPITAL CORPORATION (US) | 2014-05-01 | — | — | US | disclosed |
| US-8603818-B1 | TGF-beta receptor inhibitors to enhance direct reprogramming | THE GENERAL HOSPITAL CORPORATION (US) | 2013-12-10 | — | — | US | disclosed |
| US-8298825-B1 | TGF-beta receptor inhibitors to enhance direct reprogramming | THE GENERAL HOSPITAL CORPORATION (US) | 2012-10-30 | — | — | US | disclosed |
| US-20120021519-A1 | EFFICIENT INDUCTION OF PLURIPOTENT STEM CELLS USING SMALL MOLECULE COMPOUNDS | PRESIDENTS AND FELLOWS OF HARVARD COLLEGE (US) | 2012-01-26 | — | — | US | disclosed |
| US-20060004051-A1 | Compounds | DODIC NERINA | 2006-01-05 | — | — | US | disclosed |
| EP-1554275-A2 | COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-07-20 | — | — | EP | disclosed |
| US-20040077687-A1 | Thiazolmines and their use as tgf-beta inhibitors | GLAXO GROUP LIMITED (GB) | 2004-04-22 | — | — | US | disclosed |
| WO-2004013134-A2 | COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077687-A1 | Thiazolmines and their use as tgf-beta inhibitors | TGFBR1, TGFB1, TGFBR2 | TGFBR1 1/4885MAPK14 3537/4885CYP1A2 2095/4885 |
| US-20060004051-A1 | Compounds | SMAD3, SMAD2, TGFBR1 | TGFBR1 3/4885MAPK14 297/4885CYP1A2 4474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.